Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

HIGH EFFICACY OF ABT-493 AND ABT-530 IN HCV GENOTYPE 1 INFECTED PATIENTS WHO HAVE FAILED DAA regimens

Arm A enrolment was stopped early to investigate higher doses of study drugs in other arms. Among patients with SVR12 data, SVR12 was achieved in 6/6 (100%) Arm A patients, 20/21 (95%) Arm B patients, and 19/20 (95%) Arm C patients. Two virologic failure swere observed; 1 relapse in a nArm Bpatient with baseline NS5A RAVs, and 1 breakthrough at treatment week 8 in Arm C
in a patient with Crohn’s disease on immune suppressant therapy